TRIUMPH-1 compared retatrutide with placebo over 80 weeks. In the sponsor’s efficacy analysis, the 12 mg arm showed a 28.3% average reduction in body weight, compared with 2.2% with placebo.
80-week placebo-controlled evidence
The trial publication reports outcomes under prespecified analytical approaches. The sponsor’s headline number belongs to its stated efficacy analysis, and a reader should check the paper for how other analyses handle treatment changes or discontinuation.
How to interpret the evidence
Use the Phase 3 paper to verify the protocol and the sponsor release to trace the headline percentage to its specific table.
When comparing results, record the primary outcome, the measurement week, and whether the analysis included outcomes after treatment stopped.